A contract worth several hundred million dollars can replenish stocks without providing an answer to the outbreak currently causing concern in Central and East Africa. That is the gap at the heart of Regeneron’s announcement: the agreement strengthens the US stockpile of a treatment for one Ebola strain, while the Bundibugyo virus continues to test the tools available.
A US deal, not a treatment for the strain in circulation
On 26 October 2026, US pharmaceutical company Regeneron announced an extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US Department of Health responsible, among other things, for preparing responses to health emergencies. The agreement provides for about $270 million in payments and additional deliveries of Inmazeb to the US government through 2031.
The doses are intended to replenish US stocks for a possible response to future outbreaks. The announcement extends a partnership launched in 2020. It does not mean that the medicine is available to countries affected by the current outbreak, or that it works against the Bundibugyo strain.
This distinction is crucial for people and medical teams. Inmazeb is authorised in the United States for the disease caused by Orthoebolavirus zairense, commonly known as Zaire Ebola. To date, no specific treatment or licensed vaccine has been approved for Bundibugyo. A medicine effective against one species of the virus cannot therefore be considered effective against another without robust clinical data.
Different tools for different virus species
Inmazeb combines three monoclonal antibodies, proteins designed to recognise and neutralise a specific target: atoltivimab, maftivimab and odesivimab. The US Food and Drug Administration authorised it in 2020 to treat infections caused by Zaire Ebola. The World Health Organization subsequently prequalified it in November 2023, a step that facilitates the assessment of its quality and its possible purchase by international organisations.
In a clinical trial against this strain, the treatment reduced mortality compared with the control treatment, particularly among patients with a low viral load. But this result does not prove that the medicine works against Bundibugyo. Nor does WHO prequalification amount to approval for all Ebola virus species.
Regeneron is studying maftivimab, one of Inmazeb’s three antibodies, as a potential candidate against Bundibugyo. Laboratory experiments and studies in non-human primates have shown activity against this strain. However, these preliminary results do not establish a benefit for patients: only clinical evaluation can determine whether the candidate is safe and effective in humans.
Research is also taking shape in the region
The response to the outbreak does not depend solely on medicine stocks held abroad. It also relies on the ability to detect cases, protect healthcare workers, trace contacts and conduct trials in affected areas. In the Democratic Republic of the Congo (DRC), the National Institute of Biomedical Research (INRB) plays a central role in clinical work, alongside regional and international partners.
The PARTNERS trial, sponsored by WHO and conducted by the INRB with the Antwerp Institute of Tropical Medicine and the University of Oxford, began enrolling patients in July 2026. It is evaluating remdesivir and the experimental antibody MBP134, among other treatments. Information published on the protocol does not list maftivimab as one of the treatments currently being evaluated in the trial. This clinical study should therefore be distinguished from Regeneron’s preliminary research.
This distinction matters for Uganda too. Kampala is a regional capital connected to the eastern provinces of the DRC through trade, travel and family ties. WHO reported Bundibugyo cases in Uganda during the 2026 outbreak. Ugandan and Congolese authorities must therefore coordinate surveillance and care across borders, without conflating Uganda’s needs with those of outbreak areas in the DRC.
This cooperation takes place within the framework of the East African Community (EAC), a regional organisation that includes Uganda and the DRC, among others. Borders alone do not stop transmission. Rapid detection, information-sharing and continuity of care also matter for travellers, traders and border communities. At the same time, local health facilities must continue to meet other medical needs, particularly when resources are mobilised for an outbreak.
The next challenge: turning leads into evidence
The extension of the US contract secures a national supply of Inmazeb against Zaire Ebola. It illustrates a state’s preparedness for a health risk, but does not directly address the lack of treatment for Bundibugyo. For affected countries, the immediate priority remains access to quality care, protective equipment and treatments whose effectiveness has been demonstrated.
Research into maftivimab may broaden the range of possibilities, but it should not be presented as an established solution. Preclinical results are a step, not a therapeutic authorisation. Monitoring trials conducted in the DRC, changes in epidemiological data and any decisions by health authorities will be crucial in determining which options could genuinely benefit patients.
At the continental level, the challenge extends beyond a single molecule. It concerns the ability of African institutions to conduct trials, produce data and organise access to medical tools during emergencies. The INRB, national authorities and the Africa Centres for Disease Control and Prevention are contributing to this response. The next step will be to see whether ongoing research produces clinical evidence and treatments accessible in the countries concerned.



